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Background: To assess the reliability and accuracy of the Framingham coronary heart disease (CHD) risk
function adapted by the Registre Gironı´ del Cor (REGICOR) investigators in Spain.
Methods: A 5-year follow-up study was completed in 5732 participants aged 35–74 years. The adaptation
consisted of using in the function the average population risk factor prevalence and the cumulative incidence
observed in Spain instead of those from Framingham in a Cox proportional hazards model. Reliability and
accuracy in estimating the observed cumulative incidence were tested with the area under the curve
comparison and goodness-of-fit test, respectively.
Results: The Kaplan–Meier CHD cumulative incidence during the follow-up was 4.0% in men and 1.7% in
women. The original Framingham function and the REGICOR adapted estimates were 10.4% and 4.8%, and
3.6% and 2.0%, respectively. The REGICOR-adapted function’s estimate did not differ from the observed
cumulated incidence (goodness of fit in men, p = 0.078, in women, p = 0.256), whereas all the original
Framingham function estimates differed significantly (p,0.001). Reliabilities of the original Framingham
function and of the best Cox model fit with the study data were similar in men (area under the receiver
operator characteristic curve 0.68 and 0.69, respectively, p = 0.273), whereas the best Cox model fitted
better in women (0.73 and 0.81, respectively, p,0.001).
Conclusion: The Framingham function adapted to local population characteristics accurately and reliably
predicted the 5-year CHD risk for patients aged 35–74 years, in contrast with the original function, which
consistently overestimated the actual risk.
T
he acute myocardial infarction (AMI) mortality and
incidence rates are unexpectedly low in France and
Spain, considering the high consumption of saturated fatty
acids and the high prevalence of cardiovascular risk factors,
respectively.1–3 However, coronary heart disease (CHD) will
continue to be among the leading causes of death in these
countries.4 5 These facts demand the development of preventive
strategies adapted to local cumulative incidence and risk
factor prevalence characteristics. Individual risk stratification
is essential for such strategies.6 Unfortunately, calculations
based on the Framingham Heart Study risk functions over-
estimate the actual individual risk in Spanish patients, among
others.7–14
The Registre Gironı´ del Cor (REGICOR) investigators adapted
the Framingham function to the Spanish population character-
istics. The Framingham function was based on a Cox propor-
tional hazards model to compare individual absolute risk with
the average population risk of the corresponding sex. The
adaptation consisted of estimating the average population risk
with the risk factor prevalence and cumulative incidence
observed in Spain.1 3 15 This method to adapt the Framingham
function had been proved accurate for several ethnic groups,8 13
although the REGICOR adaptation had not been validated in
Spain.
This study examines the accuracy and reliability of the
original Framingham function and its REGICOR adaptation in
predicting 5-year CHD cumulative incidence in a Spanish
cohort aged 35–74 years recruited between 1995 and 1998.
Separate analyses were done for men, women and patients with
diabetes.
METHODS
The Validez de la Ecuacio´n de Riesgo Individual de
Framingham de Incidentes Coronarios Adaptada (Validity of
the Adapted Framingham Individual Risk Equation for
Coronary Incidents; VERIFICA) study consisted of a 5-year
follow-up of a Spanish cohort aged 35–74 years, recruited
between 1995 and 1998, initially free of symptoms of CHD and
for whom complete baseline data on risk factors were available.
Of the 5736 participants, 4430 were randomly selected from the
clinical records of 67 Spanish primary care centres that
volunteered to participate in the study. These centres covered
the most populated areas of Spain (ie, Andalusia, Aragon,
Basque Country, Balearic Islands, Catalonia, Extremadura,
Galicia, Madrid and Navarre). A prospective population-
representative cohort recruited in 1995 (n = 1306, response
rate 72% at the time of recruitment) was also included in the
study3 (fig 1). The study was approved by the local ethics
committee.
Assuming that the observed event rate would be 10% and the
minimum difference to be detected from this figure to achieve
statistical significance is 6% in the subgroup of highest risk (ie,
>10% at 5 years), the sample size provides a statistical power
.95% in men and in patients with diabetes and .80% in
women, for a 5% significance level.
Abbreviations: AMI, acute myocardial infarction; CHD, coronary heart
disease; ECG, electrocardiogram; HDL, high-density lipoprotein;
REGICOR, Registre Gironı´ del Cor; VERIFICA, Validez de la Ecuacio´n de
Riesgo Individual de Framingham de Incidentes Coronarios Adaptada
(Validity of the Adapted Framingham Individual Risk Equation for
Coronary Incidents)
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All established major cardiovascular risk factors were mea-
sured by standard methods.3 16 Participants were considered to
be diabetic if they had been diagnosed with diabetes and were
following a diabetic diet or taking drugs such as oral agents or
insulin. Participants with a history of hypertension, under
treatment for hypertension, or with systolic blood pressure
>140 mm Hg or diastolic blood pressure >90 mm Hg were
considered hypertensive. Those who reported smoking .1
cigarette/day in the preceding year were considered smokers.
All necessary baseline lipid and blood pressure measurements
were collected to estimate the risk of each participant. In the
primary care centres, the last recorded value was used unless
more than one value existed in clinical records for the year before
the date of recruitment; in that case, the average systolic and
diastolic blood pressure and the average total and high-density
lipoprotein (HDL) cholesterol from these visits were recorded.
In the population cohort, a 5-year follow-up with a personal
contact was organised to obtain an electrocardiogram (ECG)
and administer a structured questionnaire to determine
whether coronary events had occurred in the interim. All
hospital and general practitioners’ clinical records for all
hospitalised or deceased participants were examined to
ascertain the discharge diagnosis or cause of death. In fatal
cases, relatives were interviewed when deemed necessary to
clarify the cause of death.
In the retrospective primary-care cohort, medical records and
re-examination as necessary were used to identify patients who
experienced coronary events during the follow-up period.
A patient was censored at the time of the first eligible event
or at the time the final contact was established; in four cases
this was ,1 year after inclusion.
Eligible outcomes during follow-up
The CHD events considered include: (1) non-fatal AMI,
determined when hospital clinical records indicated a
characteristic ECG, enzyme or troponin increase (not explained
by other conditions), with suggestive symptoms, and the
patient survived at least 28 days after symptom onset; (2) fatal
AMI, when all AMI criteria were met and the patient died
within 28 days of symptom onset, a diagnostic necropsy existed
or sudden death occurred with suggestive symptoms that could
not be explained by other diseases (when a patient with a non-
fatal AMI died .28 days after onset of symptoms, two events
were recorded); (3) angina pectoris, when at least a positive
ischaemia test or coronary angiography was reported or
characteristic ECG changes occurred during chest pain; (4)
unrecognised AMI in the population cohort, when the follow-
up ECG showed Q waves or ischaemia signs that were absent in
the initial ECG examination and were confirmed by echo-
cardiography and cardiac scintigraphy showing signs of a
myocardial scar. All ECG were blindly interpreted and
compared with the baseline ECGs by the same senior
cardiologist.
Risk functions
All estimates were for 5-year risk. The risk functions used in
this study include the Framingham function17 and the
REGICOR adaptation to the risk factor prevalence and event
characteristics of the population in Spain.15
Statistical analysis
Clinical records from a random sample of 15% of all
participants selected in the primary care setting were re-
examined by trained external personnel for quality control
purposes. k and intra-class correlation coefficient agreement
statistics were used to determine the accuracy of data collected
by local investigators.
The cohort was divided into four groups of probability
according to the original Framingham function, using 5-year
risk cut-points at 5%, 7.5% and 10%; this represented a good
approximation to the 10%, 15% and 20% risk cut-points used in
clinical practice for 10-year risk.
Figure 1 Flowchart of participant inclusion in the combined cohorts. BP, blood pressure; CHD, coronary heart disease; HDL, high-density lipoprotein.
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The Framingham function adaptation consists essentially in
replacing the Framingham cumulative incidence and risk factor
prevalence by those of the country in which it is intended to be
applied (ie, Spain in our case). This method has been
extensively described elsewhere.7 8 15
Accuracy and reliability of the classification provided by the
original and REGICOR-adapted Framingham functions were
assessed separately by sex as follows:
1. The coefficients estimated by the Cox model that best fitted
the cohort data (best Cox) were compared with those of the
original Framingham function by a z score test.8 18 For
statistical power reasons, the model was fitted with total-
cholesterol and HDL-cholesterol as continuous variables.
2. A calibration test, by sex, assessed the accuracy of the original
Framingham and REGICOR-adapted functions by comparing
their estimated risk equations with the observed event rate in
the four risk groups established by the original Framingham
function. The D’Agostino-Nam version of the Hosmer and
Lemeshow goodness-of-fit test was used to calculate a x2
value.8 18 x2 values ,6 were considered to indicate a
substantial fit for four groups, regardless of the p value.18
3. The discrimination capacities of the original and adapted
Framingham functions were analysed by comparing the
area under the curve obtained by the receiver operator
characteristics of the original function and that obtained by
the best Cox model fit of CHD event fitted to the cohort
data. It is important to note that the adaptation procedure
does not affect discrimination.
Kaplan–Meier survival estimates were used to calculate
5-year observed cumulative incidence. The analyses were done
Table 1 Baseline characteristics and events by sex in the Spanish cohort of the Validez de la Ecuacio´n de Riesgo Individual de
Framingham de Incidentes Coronarios Adaptada (or Validity of the Adapted Framingham Individual Risk Equation for Coronary
Incidents) study
All n = 5732, n (%) Women n = 3285, n (%) Men n = 2447, n (%)
Age (years)* 56.3 (10.5) 56.8 (10.4) 55.7 (10.6)
Diagnosed diabetes 941 (16.4) 481 (14.6) 460 (18.8)
SB (mm Hg)* 135.1 (18.4) 135.2 (18.8) 135.0 (17.8)
DBP (mm Hg)* 81.4 (10.6) 80.9 (10.8) 81.9 (10.3)
Blood pressure (categories; mm Hg)
Optimal SBP,120 and DBP,80 754 (13.2) 467 (14.2) 287 (11.7%)
Normal SBP 120–129 or DBP 80–84 999 (17.4) 550 (16.7) 449 (18.3)
Normal–high SBP 130–139 or DBP 85–89 1273 (22.2) 678 (20.6) 595 (24.3)
Grade I SBP 140–159 or DBP 90–99 1925 (33.6) 1139 (34.7) 786 (32.1)
Grades II–III SBP>160 or DBP>100 781 (13.6) 451 (13.7) 330 (13.5)
Previous diagnosis of hypertension 2568 (44.8) 1549 (47.2) 1019 (41.7)
Pharmacological treatment of hypertension 1771 (30.9) 1107 (33.8) 664 (27.3)
Total cholesterol (mg/dl)* 231.8 (41.5) 234.1 (42.1) 228.8 (40.5)
Total cholesterol (mg/dl; categories)
,160 215 (3.8) 107 (3.3) 108 (4.4)
160–199 1052 (18.4) 573 (17.4) 479 (19.6)
200–239 2060 (35.9) 1152 (35.1) 908 (37.1)
240–279 1727 (30.1%) 1013 (30.8%) 714 (29.2%)
>280 678 (11.8) 440 (13.4) 238 (9.7)
HDL cholesterol (mg/dl)* 53.7 (14.7) 57.6 (14.2) 48.5 (13.6)
HDL cholesterol (mg/dl; categories)
,35 368 (6.4) 94 (2.9) 274 (11.2)
35–44 1249 (21.8) 450 (13.7) 799 (32.7)
45–49 896 (15.6) 505 (15.4) 391 (16)
50–59 1466 (25.6) 913 (27.8) 553 (22.6)
>60 1753 (30.6) 1323 (40.3) 430 (17.6)
Pharmacological treatment of cholesterol 661 (11.5) 398 (12.1) 263 (10.6)
Active smoker 1418 (24.7) 347 (10.6) 1071 (43.8)
History
Cerebrovascular disease 98 (1.7) 44 (1.3) 54 (2.2)
Congestive heart failure 67 (1.2) 39 (1.2) 28 (1.1)
Peripheral artery disease 63 (1.1) 18 (0.5) 45 (1.8)
Valve disease 89 (1.6) 45 (1.4) 44 (1.8)
Original Framingham function 5-year risk* 7.2 (6.3) 4.8 (3.7) 10.4 (7.6)
Adjusted REGICOR function 5-year risk* 2.7 (2.3) 2.0 (1.6) 3.6 (2.8)
Kaplan–Meier observed 5-year event rate (%) 3.2 1.7 4.0
Numbers of eligible outcomes
Fatal myocardial infarction 16 9 7
Non-fatal myocardial infarction (with symptoms) 44 9 35
Unrecognised myocardial infarction 3 2 1
Angina 117 48 69
Any of the above 180 68 112
DBP, diastolic blood pressure; HDL, high-density lipoprotein; REGICOR, Registre Gironı´ del Cor; SBP, systolic blood pressure.
*Mean (SD).
New Q waves observed in follow-up ECG, obtained only in the population cohort.
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with S-Plus 2000 (Insightful Corporation, Seattle, Washington,
USA) and SAS V.8.2.
RESULTS
Table 1 presents the risk factors, 5-year risk estimates and
baseline characteristics of the 5732 participants, with complete
follow-up by sex.
Quality control
The k statistics comparing the categorical data collected by the
study investigators and those extracted from clinical records by
trained independent investigators were .0.75 for risk factors
and demographic data, and .0.84 for type of event during
follow-up. Intraclass correlation coefficients (age, total and
HDL cholesterol, systolic and diastolic blood pressure) were
.0.90 in all instances, indicating good to excellent agreement.
Follow-up
The observed number of patients with at least one CHD event
was 180 (table 1); 41% of 5-year overall CHD and 69.8% of fatal
CHD events occurred after age 65 years. In addition, 24 fatal
non-CHD cardiovascular events and 107 non-cardiovascular
deaths were observed during follow-up. Only four patients were
lost to follow-up.
The original Framingham function overestimated the
observed event rate in women and men by a factor of 2.8 and
2.6, respectively. The REGICOR-adapted function improved
substantially the goodness of fit for both sexes: the distribution
of observed events did not differ from that predicted by the
adapted function (fig 2).
We fitted a proportional hazards Cox model with the cohort
data to estimate the b coefficients for each risk factor level.
None of the coefficients significantly differed from the original
Framingham function in men and only that of smoking
differed in women (table 2).
The area under the receiver operator characteristic curve
obtained with the best-fitting Cox function was similar to that
of the original Framingham function in men, indicating a
similar discrimination capacity. By contrast, the best Cox model
fit provided a higher area under the curve than the original
function in women, suggesting that the coefficients estimated
with local data significantly improved the identification of
women who developed an event during follow-up (fig 3).
In men and women with diabetes (n = 941), the Kaplan–
Meier observed overall 5-year CHD event rate was 4.9%. The
original Framingham function significantly overestimated the
event rate by a factor .2.6; the prediction of the REGICOR-
adapted function did not differ from the observed rate (fig 4).
DISCUSSION
The study findings show that the accuracy of the CHD risk
estimated by the REGICOR-adapted function is better than that
of the original Framingham function in Spanish men, women
and patients with diabetes. The REGICOR adaptation has
proved to reliably provide accurate CHD risk estimates for ages
35–74 years in Spain. The adaptation method is a valid
instrument for CHD risk assessment in countries with
cardiovascular risk factor and event rate characteristics
different from those of the Framingham population.
An overestimation of risk by the Framingham function has
been shown to exist not only in the Spanish population7 but
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Figure 2 Distribution of participants, by sex, in four groups of coronary
heart disease risk according to the 5-year Framingham function, showing
the observed event rate and the rate expected by the REGICOR-adapted
and original Framingham functions, together with the goodness-of-fit x2
statistics and significance levels.
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also in northern and western European countries.9–12 For
example, an overestimation of about 60% was observed in the
UK14; however, this is far from the .260% overestimation
observed in Spain.7 The greater magnitude of the overestima-
tion in Spain may be related to the fact that the relative risk of
CHD for higher values of total cholesterol and blood pressure as
compared with lowest values is similar in all countries, but the
absolute risk strongly depends on the country where data are
gathered.19 20 If we are to adequately predict CHD risk in areas
where the AMI incidence rate is, comparatively, very low, we
need to urgently adapt the Framingham function to the
population characteristics of those countries, to prevent over-
treatment, particularly with lipid-lowering drugs, stemming
from risk overestimation.
The accuracy of risk estimates is a key to determine the best
primary prevention strategies, and has important practical
implications. For example, even in regions of high CHD
incidence, the low cost effectiveness of statin use in primary
prevention makes it difficult for public health services to
assume this expense.21–23 Primary prevention in Spain, a country
of low CHD incidence (eg, half to one-third the incidence in
UK),1 is even less cost effective. The effectiveness and safety of
long-term primary prevention with statins remains uncertain,
at least in patients with low-to-moderate coronary risk.24 25
Characteristics and limitations of the study
Hypertension and lipid-lowering drugs may be independent
factors that modulate the coefficient estimates for risk factors.
In our study, none of these treatments was independently
associated with event occurrence in either sex (data not
shown). However, the best Cox model fit was adjusted for both.
The fact that the coefficient for smoking was significantly
higher for women in the best Cox model fit than for those in
the original function suggests that smoking may be more
relevant to CHD development for women in Spain, where the
incidence rate for smoking is much lower than that in
Framingham. It should be noted, of course, that the prevalence
of smoking in younger women in Spain was much lower than
in Framingham 30 years ago, but has been increasing in recent
years. However, the cumulative incidence observed in the last
15 years in Spain still corresponds to the effects of low exposure
to smoking 30 years ago. Therefore, applying the Framingham
b for smoking in Spain may still lead to an overestimation of
the effect, given the lag in women’s exposure to smoking.
We used the population-based sample to test whether any
difference existed in the results as compared with the overall cohort.
Beyond the sample size restrictions, no substantial differences
were found (results not shown) in this subgroup analysis.
The diabetic subgroup showed a higher 5-year event rate
(5.3%) and higher risk (2.5%) than the rest of the general
population in our study. The latest publications have found the
event risk in CHD patients without diabetes to be 1.9 times
higher than that in CHD-free patients with diabetes.26 A
controversy exists as to whether the increased cardiovascular
risk of patients with diabetes should lead to secondary
prevention intervention in these patients.27–29 These findings
support the principle of applying caution in this context:
patients with diabetes should be more carefully followed and
may need more intensive regimens of treatment with drugs, but
it is difficult to accept that they must be assigned the same level
of risk as patients offered secondary prevention. We could not
Table 2 Estimates of the coefficients for each variable included in the Framingham original function and in the best Cox model
adjusted for treatments for hypertension and lipid lowering, by sex
Men Women
Framingham
original REGICOR Best Cox z score Framingham original REGICOR Best Cox z-score
Coef SE Coef SE p Value Coef SE Coef SE p Value
Age 0.049 0.005 00 43 0.012 0.631 0.338 0.074 0.291 0.222 0.84
Age .2 years — — — — — 20.003 0.001 20.002 0.002 0.56
Total cholesterol (1 mg) 0.007 0.001 0.002 0.003 0.067 0.005 0.002 20.001 0.004 0.119
HDL cholesterol (1 mg) 20.027 0.005 20.02 0.009 0.485 20.027 0.005 20.048 0.012 0.093
Blood pressure classification
Optimal SBP,120 and
DBP,80 mm Hg
20.009 0.194 20.589 0.522 0.298 20.52 0.256 20.014 0.704 0.499
Normal SBP 120–129 or
DBP 80–84 mm Hg
— — — — — — — — — —
Normal-high SBP 130–139 or
DBP 85–89 mm Hg
0.275 0.171 20.147 0.358 0.288 20.047 0.231 20.043 0.495 0.992
HT Grade I SBP 140–159 or
DBP 90–99 mm Hg
0.524 0.159 0.339 0.321 0.604 0.269 0.205 20.046 0.444 0.52
HT Grades II-III SBP>160 or
DBP>100 mm Hg
0.631 0.173 0.126 0.408 0.254 0.485 0.218 0.162 0.499 0.553
Diagnosed diabetes 0.417 0.177 0.017 0.259 0.201 0.617 0.212 0.798 0.3 0.622
Current smoker 0.53 0.104 0.564 0.215 0.886 0.235 0.142 1.382 0.44 0.017
Coef, coefficient in the proportional hazards regression model; DBP, diastolic blood pressure; HDL, high-density lipoprotein; HT, hypertension; REGICOR, Registre
Gironı´ del Cor; SBP, systolic blood pressure.
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and original Framingham functions.
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undertake appropriate subgroup analysis of patients with
diabetes by sex due to limited statistical power.
The fatal and symptomatic non-fatal AMI annual incidence
rate observed in our study is higher than that observed in Spain
in the population aged 35–74 years (122 and 81 per 100 000
women, and 420 and 314 per 100 000 men, respectively), which
is consistent with the predominantly primary care origin of the
studied cohort.30
In summary, the original Framingham function applied to the
Spanish population significantly overestimated the 5-year observed
CHD rate. However, the adapted function reliably and accurately
predicted the observed 5-year CHD cumulative incidence.
Adaptation of the Framingham function is a valid alternative to
the creation of new functions derived from local cohorts.
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